

for each individual were run on 3% NuSieve gels in 0.5X TBE to confirm that the reaction worked.

Amendments to the specification are indicated in the attached “Marked Up Version of Amendments” (pages i - iii).

In the Claims

Please cancel Claims 1-30 and 45-72.

Please amend Claims 31 and 36. Amendments to the claims are indicated in the attached “Marked Up Version of Amendments” (page iii).

31. (Amended) A method of determining increased likelihood of a vascular disease in a human, comprising
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene in a nucleic acid sample obtained from a human, wherein presence of a C at nucleotide position 1186 is indicative of increased likelihood of a vascular disease in the human as compared with a human having an G at nucleotide position 1186, thereby determining increased likelihood of vascular disease in a human.

36. (Amended) A method of determining decreased likelihood of a vascular disease in a human comprising
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene in a nucleic acid sample obtained from a human, wherein presence of a G at nucleotide position 1186 is indicative of decreased likelihood of a vascular disease in the human as compared with a human having a C at nucleotide position 1186, thereby determining decreased likelihood of a vascular disease in a human.

Please add new Claims 73-80.

73. (New) A method for predicting the likelihood that a human will have myocardial infraction, comprising:
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene in a nucleic acid sample obtained from a human, wherein presence of a C at nucleotide position 1186 is indicative of increased likelihood of a myocardial infraction in the human as compared with a human having a G at nucleotide position 1186, thereby predicting the likelihood that a human will have myocardial infraction.
74. (New) The method according to Claim 73, wherein the thrombospondin-4 gene has the nucleotide sequence of SEQ ID NO: 3.
75. (New) A method for predicting the likelihood that a human will have coronary revascularization, comprising:
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene from a nucleic acid sample obtained from a human, wherein presence of a C at nucleotide position 1186 is indicative of increased likelihood of a coronary revascularization in the human as compared with a human having a G at nucleotide position 1186, thereby predicting the likelihood that a human will have coronary revascularization.
76. (New) The method according to Claim 75, wherein the thrombospondin-4 gene has the nucleotide sequence of SEQ ID NO: 3.
77. (New) A method for predicting the likelihood that a human will have myocardial infraction, comprising:
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene in a nucleic acid sample obtained from a human,

wherein presence of a G at nucleotide position 1186 is indicative of decreased likelihood of a myocardial infraction in the human as compared with a human having a C at nucleotide position 1186, thereby predicting the likelihood that a human will have myocardial infraction.

78. (New) The method according to Claim 77, wherein the thrombospondin-4 gene has the nucleotide sequence of SEQ ID NO: 3.
79. (New) A method for predicting the likelihood that a human will have coronary revascularization, comprising:
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene from a nucleic acid sample obtained from a human, wherein presence of a G at nucleotide position 1186 is indicative of decreased likelihood of a coronary revascularization in the human as compared with a human having a C at nucleotide position 1186, thereby predicting the likelihood that a human will have coronary revascularization.
80. (New) The method according to Claim 79, wherein the thrombospondin-4 gene has the nucleotide sequence of SEQ ID NO: 3.

REMARKS

Claim Amendments

Claims 31-46 are pending. New claims 73-80 have been added. Support for these claims can be found throughout the specification, for example at page 7, lines 4 -16. Dependent Claims 45 and 46 have been cancelled in favor of newly added Claims 73, 75, 77 and 79. In addition, non-elected claims 1-30 and 47-72 have been cancelled. Claims 31 and 36 have been amended. Support for the amendments can be found, for example, on page 7, lines 17-26. No new matter has been added.